[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100419234":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":136,"collaborators":10,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":10,"eligibilityCriteria":144,"healthyVolunteers":140,"sex":145,"minAge":146,"maxAge":10,"enrollmentInfo":147,"targetDuration":10,"studyType":150,"phases":10,"briefSummary":151,"conditions":152,"keywords":10,"overallStatus":110,"whyStopped":10,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ancillary-correlative (biospecimen collection)",null,"Patients undergo collection of blood samples at baseline, during each neoadjuvant therapy treatment, prior to surgical resection, and up to 4 times per year for up to 5 years. Patients also undergo collection of tissue sample at time of surgical resection. Patients medical records may also be reviewed.",[13,14],"Procedure: Biospecimen Collection","Other: Electronic Health Record Review",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"PROCEDURE","Biospecimen Collection","Undergo collection of blood and tissue samples",[9],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Electronic Health Record Review","Review of medical records",[9],[26],{"name":27,"affiliation":5,"role":28},"Arvind Dasari","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":10,"email":33},"CONTACT","(713) 792-2828","adasari@mdanderson.org",[35,49,59,69,79,89,99,108,118,127],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":10},"Banner - MD Anderson Cancer Center","TERMINATED","Gilbert","Arizona","85234","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-111.78903,33.35283,{"lat":47,"lon":46},{"facility":50,"status":37,"city":51,"state":52,"zip":53,"country":41,"countryCode":42,"cosmosGeoPoint":54,"geoPoint":58,"contacts":10},"Baptist- MD Anderson Cancer Center","Jacksonville","Florida","32207",{"type":44,"coordinates":55},[56,57],-81.65565,30.33218,{"lat":57,"lon":56},{"facility":60,"status":37,"city":61,"state":62,"zip":63,"country":41,"countryCode":42,"cosmosGeoPoint":64,"geoPoint":68,"contacts":10},"The Queen's Medical Center","Honolulu","Hawaii","96813",{"type":44,"coordinates":65},[66,67],-157.85833,21.30694,{"lat":67,"lon":66},{"facility":70,"status":37,"city":71,"state":72,"zip":73,"country":41,"countryCode":42,"cosmosGeoPoint":74,"geoPoint":78,"contacts":10},"St. Luke's Cancer Institute","Boise","Idaho","83712",{"type":44,"coordinates":75},[76,77],-116.20345,43.6135,{"lat":77,"lon":76},{"facility":80,"status":37,"city":81,"state":82,"zip":83,"country":41,"countryCode":42,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Cooper Hospital UNIV MED CTR.","Camden","New Jersey","08103",{"type":44,"coordinates":85},[86,87],-75.11962,39.92595,{"lat":87,"lon":86},{"facility":90,"status":37,"city":91,"state":92,"zip":93,"country":41,"countryCode":42,"cosmosGeoPoint":94,"geoPoint":98,"contacts":10},"UT Southwestern\u002FSimmons Cancer Center-Dallas","Dallas","Texas","75390",{"type":44,"coordinates":95},[96,97],-96.80667,32.78306,{"lat":97,"lon":96},{"facility":100,"status":37,"city":101,"state":92,"zip":102,"country":41,"countryCode":42,"cosmosGeoPoint":103,"geoPoint":107,"contacts":10},"Houston Methodist Cancer Center","Houston","77030",{"type":44,"coordinates":104},[105,106],-95.36327,29.76328,{"lat":106,"lon":105},{"facility":109,"status":110,"city":101,"state":92,"zip":102,"country":41,"countryCode":42,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"M D Anderson Cancer Center","RECRUITING",{"type":44,"coordinates":112},[105,106],{"lat":106,"lon":105},[115,117],{"name":27,"role":31,"phone":116,"phoneExt":10,"email":33},"713-792-2828",{"name":27,"role":28,"phone":10,"phoneExt":10,"email":10},{"facility":119,"status":37,"city":120,"state":92,"zip":121,"country":41,"countryCode":42,"cosmosGeoPoint":122,"geoPoint":126,"contacts":10},"UT Health San Antonio MD Anderson Cancer Center","San Antonio","78229",{"type":44,"coordinates":123},[124,125],-98.49363,29.42412,{"lat":125,"lon":124},{"facility":128,"status":37,"city":129,"state":92,"zip":130,"country":41,"countryCode":42,"cosmosGeoPoint":131,"geoPoint":135,"contacts":10},"Baylor Scott & White Research Institute","Temple","76508",{"type":44,"coordinates":132},[133,134],-97.34278,31.09823,{"lat":134,"lon":133},{"type":137,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100419234","minimal-residual-disease-assessment-in-patients-with-colorectal-cancer-the-mirda-c-study-100419234",false,"NCT04739072","Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study","Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histological\u002Fcytological confirmation of colorectal adenocarcinoma.\n3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.\n4. Ability to understand and the willingness to sign a written informed consent document.\n5. Willing to pursue standard of care surveillance post completion of curative therapies.\n6. Willing to provide blood samples for correlative research.\n\nExclusion Criteria:\n\n1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and \u002F or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.\n2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.","ALL","18 Years",{"count":148,"type":149},1000,"ESTIMATED","OBSERVATIONAL","This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules\u002Fchemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.",[153,154,155,156,157,158,159,160,161,162,163,164,165,166],"Colorectal Adenocarcinoma","Stage I Colorectal Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage IIA Colorectal Cancer AJCC v8","Stage IIB Colorectal Cancer AJCC v8","Stage IIC Colorectal Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v6","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8","2026-05-27",{"date":169,"type":170},"2026-05-29","ACTUAL",{"date":172,"type":170},"2019-11-22",{"date":174,"type":149},"2028-12-31",{"name":5,"class":6},10]